Medidata Solutions (MDSO) Getting Somewhat Positive News Coverage, Study Shows
Press coverage about Medidata Solutions (NASDAQ:MDSO) has been trending somewhat positive recently, Accern Sentiment Analysis reports. The research group scores the sentiment of media coverage by reviewing more than twenty million blog and news sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Medidata Solutions earned a media sentiment score of 0.11 on Accern’s scale. Accern also gave news stories about the company an impact score of 46.5701713527191 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the near term.
Here are some of the media headlines that may have impacted Accern Sentiment Analysis’s rankings:
- A Look at Valuation For Shares of Medidata Solutions Inc (MDSO) (newstrendstoday.com)
- Zacks: Analysts Anticipate Medidata Solutions, Inc. (NASDAQ:MDSO) Will Post Quarterly Sales of $141.03 Million (americanbankingnews.com)
- IHS Markit Score downgrades Medidata Solutions Inc to 32 out of 100, ranking positively in only one out of three available IHS Markit categories. (finance.yahoo.com)
- Brokerages Expect Medidata Solutions, Inc. (MDSO) Will Post Earnings of $0.19 Per Share (americanbankingnews.com)
- Medidata Earns Recognition as Leading Innovative Company and a Great Place to Work® (finance.yahoo.com)
MDSO has been the topic of several research reports. BidaskClub downgraded Medidata Solutions from a “buy” rating to a “hold” rating in a report on Wednesday, June 14th. SunTrust Banks, Inc. raised their price objective on Medidata Solutions from $80.00 to $90.00 and gave the stock a “buy” rating in a report on Tuesday, June 27th. KeyCorp lifted their price target on Medidata Solutions from $71.00 to $74.00 and gave the company an “overweight” rating in a report on Thursday, May 11th. J P Morgan Chase & Co lifted their price target on Medidata Solutions to $87.00 and gave the company an “overweight” rating in a report on Tuesday, July 18th. Finally, Citigroup Inc. reiterated a “buy” rating and issued a $94.00 price target (up from $77.00) on shares of Medidata Solutions in a report on Monday, July 10th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and eleven have given a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and an average price target of $78.17.
Shares of Medidata Solutions (MDSO) opened at 72.84 on Friday. The stock has a 50 day moving average price of $77.92 and a 200-day moving average price of $66.27. Medidata Solutions has a 52-week low of $46.10 and a 52-week high of $85.92. The firm has a market cap of $4.12 billion, a PE ratio of 117.67 and a beta of 1.79.
Medidata Solutions (NASDAQ:MDSO) last issued its earnings results on Tuesday, July 18th. The company reported $0.31 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.28 by $0.03. Medidata Solutions had a net margin of 7.07% and a return on equity of 11.14%. The company had revenue of $137.41 million during the quarter, compared to analysts’ expectations of $134.28 million. During the same period last year, the company posted $0.24 earnings per share. The firm’s quarterly revenue was up 19.9% compared to the same quarter last year. On average, equities analysts anticipate that Medidata Solutions will post $1.28 EPS for the current fiscal year.
In other Medidata Solutions news, COO Michael L. Capone sold 5,000 shares of the stock in a transaction dated Monday, May 15th. The shares were sold at an average price of $69.46, for a total value of $347,300.00. Following the completion of the transaction, the chief operating officer now directly owns 171,754 shares of the company’s stock, valued at $11,930,032.84. The sale was disclosed in a filing with the SEC, which is available at this link. Also, Director Robert Taylor sold 5,639 shares of the stock in a transaction dated Monday, June 5th. The shares were sold at an average price of $73.46, for a total transaction of $414,240.94. Following the completion of the transaction, the director now directly owns 54,372 shares of the company’s stock, valued at $3,994,167.12. The disclosure for this sale can be found here. Company insiders own 5.80% of the company’s stock.
TRADEMARK VIOLATION WARNING: “Medidata Solutions (MDSO) Getting Somewhat Positive News Coverage, Study Shows” was originally reported by Daily Political and is owned by of Daily Political. If you are viewing this piece of content on another publication, it was stolen and republished in violation of United States & international trademark & copyright legislation. The legal version of this piece of content can be read at https://www.dailypolitical.com/2017/08/12/medidata-solutions-mdso-getting-somewhat-positive-news-coverage-study-shows.html.
About Medidata Solutions
Medidata Solutions Inc (Medidata) is a provider of cloud-based solutions for life sciences. The Company provides cloud-based solutions for clinical research in life sciences, offering platform technology that focuses on the clinical development. The Company’s plan study addresses three areas to ensure optimal study design, grant development and negotiation, and investigator payments.
Receive News & Ratings for Medidata Solutions Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medidata Solutions Inc. and related companies with MarketBeat.com's FREE daily email newsletter.